ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024, at 8:30 a.m. ET
ANI Pharmaceuticals, Inc. will release its fourth quarter and full year 2023 financial results on February 29, 2024. The conference call will be hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey. The call will be available for replay on the company's website.
02/07/2024 - 06:50 AM
BAUDETTE, Minn., Feb. 07, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2023 financial results on Thursday, February 29, 2024, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, and Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, will host a conference call to discuss the results as follows:
Date Thursday, February 29, 2024 Time 8:30 a.m. ET Toll free (U.S.) 800-274-8461 Webcast (live and replay) www.anipharmaceuticals.com , under the “Investors” section
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-8531 and entering access code 4470257.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceutical products, including for diseases with high unmet medical need. Our team is focused on delivering sustainable growth by scaling up our Rare Disease business through the successful launch of our lead asset, Purified Cortrophin® Gel, strengthening our generics business with enhanced research and development capability, innovation in established brands and leveraging our North American manufacturing capabilities. For more information, please visit our website www.anipharmaceuticals.com .
Investor Relations Contact: lwilson@insitecony.com
SOURCE: ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals will release its fourth quarter and full year 2023 financial results on February 29, 2024.
The conference call will be hosted by President and CEO Nikhil Lalwani and CFO Stephen P. Carey.
The replay of the conference call will be available on the company's website under the 'Investors' section.
The replay of the conference call will be accessible for two weeks.
ANIP Rankings
#367 Ranked by Stock Gains
ANIP Stock Data
Industry
Biological Product (except Diagnostic) Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Other, Manufacturing, Biological Product (except Diagnostic) Manufacturing
Country
US
City
Baudette
About ANIP
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
